RESUMO
BACKGROUND: More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial. METHODS: We conducted a blinded, 2-by-2 factorial trial in which 210 patients with pleural infection were randomly assigned to receive one of four study treatments for 3 days: double placebo, intrapleural tissue plasminogen activator (t-PA) and DNase, t-PA and placebo, or DNase and placebo. The primary outcome was the change in pleural opacity, measured as the percentage of the hemithorax occupied by effusion, on chest radiography on day 7 as compared with day 1. Secondary outcomes included referral for surgery, duration of hospital stay, and adverse events. RESULTS: The mean (±SD) change in pleural opacity was greater in the t-PA-DNase group than in the placebo group (-29.5±23.3% vs. -17.2±19.6%; difference, -7.9%; 95% confidence interval [CI], -13.4 to -2.4; P=0.005); the change observed with t-PA alone and with DNase alone (-17.2±24.3 and -14.7±16.4%, respectively) was not significantly different from that observed with placebo. The frequency of surgical referral at 3 months was lower in the t-PA-DNase group than in the placebo group (2 of 48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for surgical referral, 0.17; 95% CI, 0.03 to 0.87; P=0.03) but was greater in the DNase group (18 of 46 patients [39%]) than in the placebo group (odds ratio, 3.56; 95% CI, 1.30 to 9.75; P=0.01). Combined t-PA-DNase therapy was associated with a reduction in the hospital stay, as compared with placebo (difference, -6.7 days; 95% CI, -12.0 to -1.9; P=0.006); the hospital stay with either agent alone was not significantly different from that with placebo. The frequency of adverse events did not differ significantly among the groups. CONCLUSIONS: Intrapleural t-PA-DNase therapy improved fluid drainage in patients with pleural infection and reduced the frequency of surgical referral and the duration of the hospital stay. Treatment with DNase alone or t-PA alone was ineffective. (Funded by an unrestricted educational grant to the University of Oxford from Roche UK and by others; Current Controlled Trials number, ISRCTN57454527.).
Assuntos
Desoxirribonucleases/uso terapêutico , Fibrinolíticos/uso terapêutico , Doenças Pleurais/tratamento farmacológico , Derrame Pleural/tratamento farmacológico , Ativador de Plasminogênio Tecidual/uso terapêutico , Adulto , Idoso , Desoxirribonucleases/efeitos adversos , Método Duplo-Cego , Feminino , Fibrinolíticos/efeitos adversos , Humanos , Instilação de Medicamentos , Análise de Intenção de Tratamento , Modelos Lineares , Pulmão/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Doenças Pleurais/diagnóstico por imagem , Doenças Pleurais/mortalidade , Derrame Pleural/diagnóstico por imagem , Radiografia , Ativador de Plasminogênio Tecidual/efeitos adversosAssuntos
Derrame Pleural/terapia , Pneumotórax/terapia , Ultrassonografia de Intervenção/métodos , Algoritmos , Assepsia/métodos , Tubos Torácicos , Competência Clínica , Educação de Pós-Graduação em Medicina/métodos , Humanos , Posicionamento do Paciente/métodos , Derrame Pleural/diagnóstico por imagem , Pneumotórax/diagnóstico por imagem , Pneumologia/educação , Sucção/efeitos adversos , Sucção/instrumentação , Sucção/métodos , Tórax/diagnóstico por imagemRESUMO
Silicon granuloma is one of the benign complications of breast implant failure but this is rarely reported. We report a 66-year-old lady presented to respiratory department with history of weight loss and a chest x-ray was highly suggestive of a lung malignancy. Further investigation including CT thorax and breast ultrasound suggested siliconoma that was later on confirmed on tissue biopsy.
Assuntos
Implantes de Mama/efeitos adversos , Mama/patologia , Granuloma de Corpo Estranho/diagnóstico , Neoplasias Pulmonares/diagnóstico , Elastômeros de Silicone/efeitos adversos , Idoso , Biópsia , Diagnóstico Diferencial , Feminino , Humanos , Radiografia Torácica , Tomografia Computadorizada por Raios XRESUMO
AIMS: Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment. At high doses they can give rise to systemic side-effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression. This effect may depend on the delivery system, which in turn alters drug deposition and adsorption. We hypothesized that adrenal suppression depends on the rate of steroid absorption rather than the total steroid dose received. METHODS: Eight healthy adult males were recruited for a randomized double-blind placebo controlled trial. Adrenocortical suppression ability was demonstrated by a 30% suppression of early morning cortisol following 1 mg dexamethasone. Subjects then attended in the evening on two occasions receiving 500 microg of intravenous beclomethasone monopropionate (17-BMP) for either 15 min or 2 h. Overnight urinary cortisol : creatinine (C : C) ratio was measured before and after the infusion and an 08.00 h serum cortisol was measured following the infusion. RESULTS: Mean C : C pre and post 15 min infusion was 5.97 and 3.22 (P = 0.005). Mean C : C pre and post 2 h infusion was 6.31 and 4.15 (P = 0.004). Delta C : C and mean 08.00 h cortisol for 15 min and 2 h infusion was 2.74 and 2.16 and 425 nmol l(-1) and 400 nmol l(-1), respectively (P = NS). CONCLUSIONS: The rate of infusion of 17-BMP seemed to have little effect on the degree of adrenal suppression. Individual C : C ratios were reproducible. Differences in absorption of ICS are unlikely to explain observed differences in HPA axis suppression.